20/20 BioLabs and IBM collaboration signals new direction in preventive diagnostics
20/20 BioLabs launches AI-powered OneTest for longevity risk modeling. Discover what this means for preventive diagnostics and regulation.
How subcutaneous amivantamab approval in Europe could reshape EGFR-mutated NSCLC treatment workflows
EU approves subcutaneous amivantamab for expanded EGFR lung cancer dosing. Discover what this changes for clinicians and health systems.
Can PharmAla’s three year stability program de risk MDMA distribution challenges?
PharmAla will generate three year stability data for LaNeo MDMA. Discover how this could shape packaging, regulation, and commercialization.
Recursion Pharmaceuticals to spotlight self-driving lab model at NVIDIA GTC 2026
Recursion Pharmaceuticals spotlights its self-driving lab model at NVIDIA GTC 2026. Explore what this means for AI drug discovery and regulation.
Next-generation SIGNA MRI gains FDA nod, sharpening GE HealthCare’s imaging strategy
GE HealthCare secures FDA clearance for next-generation SIGNA MRI. Explore clinical impact, workflow gains, and market implications.
Dror Ortho-Design advances U.S. commercialization with next-generation ZSmile Platform
Dror Ortho-Design secures FDA clearance for ZSmile. Explore what pneumatic aligners mean for orthodontic innovation and adoption.
Profusa Lumee Oxygen gains pre-approval orders as EU MDR decision looms
Profusa secures Lumee Oxygen orders ahead of EU MDR clearance. Discover what this means for CLTI monitoring and 2026 commercialization.
Starton Therapeutics advances STAR-LLD as delivery innovation in multiple myeloma
Starton Therapeutics advances STAR-LLD in Phase 2a. Explore how continuous lenalidomide delivery could reshape multiple myeloma care.
Moleculin Biotech, Inc. secures Japanese IP boost as Annamycin enters pivotal Phase 3
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.
FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.